Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MRUS
- Price
- 39.56
- Stock movement up
- +4.67 (13.38%)
- Company name
- Merus BV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 2.71B
- Ent værdi
- 2.42B
- Pris/omsætning
- 75.38
- Pris/bog
- 3.85
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 19.24%
- 1 års afkast
- -10.11%
- 3 års afkast
- 12.22%
- 5 års afkast
- 30.38%
- 10 års afkast
- -
Senest opdateret: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
MRUS betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 75.38 |
| Pris til egenkapital | 3.85 |
| EV i forhold til salg | 67.26 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 68.46M |
| EPS (TTM) | -3.58 |
| FCF pr. aktie (TTM) | -2.28 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 35.93M |
| Bruttofortjeneste (TTM) | -1.53M |
| Driftsindkomst (TTM) | -230.96M |
| Nettoindkomst (TTM) | -244.56M |
| EPS (TTM) | -3.58 |
| EPS (1 år frem) | -3.78 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | -4.25% |
| Driftsmargin (TTM) | -642.76% |
| Fortjenstmargin (TTM) | -680.61% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 433.00M |
| Nettotilgodehavender | 3.88M |
| Omsætningsaktiver i alt | 666.28M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 1.86M |
| Ejendomme, anlæg og udstyr | 22.46M |
| Sum aktiver | 844.68M |
| Kreditor | 6.18M |
| Kortfristet/nuværende langsigtet gæld | 1.76M |
| Summen af kortfristede forpligtelser | 80.08M |
| Sum gæld | 141.41M |
| Aktionærernes egenkapital | 703.26M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -153.91M |
| Investeringsudgifter (TTM) | 1.72M |
| Fri pengestrøm (TTM) | -155.63M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -34.77% |
| Afkast af aktiver | -28.95% |
| Afkast af investeret kapital | -34.60% |
| Kontant afkast af investeret kapital | -22.02% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 34.08 |
| Daglig høj | 40.00 |
| Daglig lav | 33.19 |
| Daglig volumen | 1.06M |
| Højeste gennem alle tider | 60.20 |
| 1 års analytiker estimat | 86.07 |
| Beta | 1.13 |
| EPS (TTM) | -3.58 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 6 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| MRUS | S&P500 | |
| Nuværende prisfald fra top notering | -34.29% | -10.49% |
| Højeste prisfald | -67.42% | -56.47% |
| Højeste efterår dato | 3 Apr 2020 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -34.64% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 45 days | 12 days |
| Maks. tid til nyt højdepunkt | 1211 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
2.71B
Markedsværdi kategori
Mid-cap
Beskrivelse
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Personale
172
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Sven Ante Lundberg
Land
USA
By
Utrecht 3584
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
iO Charts is a Seeking Alpha partnerNæste side